Safety data sheet. GHS / OSHA HCS 2012 format, 16 sections. Issued by Epic Peptides Lab for the catalogue items listed in Section 1.

Epic Peptides Lab

Safety data sheet · solution, preloaded autoinjector pen

Epic Peptides Lab · USA

Document number: PL-SDS-163
Revision: 1.0 · 2026-10-03

Tesamorelin

solution, preloaded autoinjector pen

WARNING

1Identification

Product Identifier

Tesamorelin

Document Number

PL-SDS-163

Catalogue Items Covered

Id
20633
Name
Preloaded Autoinjector | Tesamorelin | 3ml Pen | 10mg
Sku
PL-TESA-3ML-PEN

Recommended Use

Laboratory research use by trained personnel.

Restrictions On Use

Not for human or veterinary use.

Supplier / Distributor

Epic Peptides Lab, USA

Telephone

+1 (787) 468-5291

info@epicpeptideslab.com

2Hazard(s) identification

Classification

Reproductive toxicity — Category 2 — H361

Label Elements

Pictograms: GHS08
Signal: Warning
Hazard statements: H361 Suspected of damaging fertility or the unborn child.
Precautionary statements: P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing and eye protection.

P308+P313 IF exposed or concerned: Get medical advice/attention.

P405 Store locked up.

P501 Dispose of contents and container to an approved waste disposal plant in accordance with local, state and federal regulations.

Signal Word

Warning

Other Hazards

No data available.

3Composition / information on ingredients

Description

Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle.

Composition

Name
Tesamorelin
Full
Tesamorelin (trans-3-hexenoyl-GHRH(1-44)-NH2)
Cas
218949-48-5
Formula
C221H366N72O67S
Conc
0.33% w/v
Qty
10 mg per 3 mL pen
Hazards
- Reproductive toxicity — Category 2 — H361
Name
Benzyl alcohol (preservative)
Full
Benzyl alcohol, antimicrobial preservative (0.9% w/v in bacteriostatic water)
Cas
100-51-6
Formula
C7H8O
Conc
0.9% w/v
Hazards
- Acute toxicity, oral — Category 4 — H302
- Acute toxicity, inhalation — Category 4 — H332
- Serious eye damage/eye irritation — Category 2A — H319
- Skin sensitisation — Category 1B — H317
Name
Water for injection
Full
Water for injection
Cas
7732-18-5
Formula
H2O
Conc
balance to 100%

4First-aid measures

First Aid Measures

Inhalation: Move the person to fresh air and keep comfortable for breathing. If breathing is difficult or symptoms persist, call a POISON CENTER or doctor.
Skin: Take off contaminated clothing. Wash the skin with plenty of soap and water. If irritation or a rash develops, get medical advice.
Eyes: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do; continue rinsing. If eye irritation persists, get medical advice.
Ingestion: Rinse mouth. Do not induce vomiting. Call a POISON CENTER or doctor if you feel unwell.
Injection: For an accidental needle-stick: wash the site with soap and water, do not squeeze, cover with a dressing and seek medical advice; report the incident according to your laboratory's sharps procedure.
General: If exposed or concerned, get medical advice. Show this safety data sheet to the doctor. Pregnant or nursing laboratory staff should avoid exposure.

Most Important Symptoms And Effects

No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

Likely Routes Of Exposure

Accidental needle-stick injection; skin and eye contact from splashes; ingestion is unlikely.

5Fire-fighting measures

Fire Fighting Information: Aqueous solution containing 0.9% benzyl alcohol; not flammable and does not support combustion.

6Accidental release measures

Spill And Clean Up Procedures: Absorb small spills with paper towel or an inert absorbent, place in a sealed container for disposal and clean the area with water and detergent. Pick up broken glass with tongs or forceps, never by hand.

7Handling and storage

Safe Handling: Handle the device as a sharp: never recap or reuse needles, keep fingers away from the needle, and discard used devices into a rigid sharps container. Avoid splashes to eyes and skin. Wash hands after handling.
Safe Storage: Store at 2–8 °C in the original carton, protected from light. Do not freeze; discard if the solution has frozen or is discoloured or cloudy. Once in use, keep the device capped between uses.
Storage Temperature: 2–8 °C, protected from light; do not freeze
Incompatible Materials: No further relevant information available (Cayman); generic: strong oxidizing agents, strong acids/bases

8Exposure controls / personal protection

Occupational Exposure Limits: Benzyl alcohol: no OSHA PEL, ACGIH TLV or NIOSH REL; AIHA WEEL 10 ppm (44 mg/m³) 8-h TWA. Present at 0.9%.

No occupational exposure limits have been established for the active ingredient(s).
Exposure Controls And PPE: No data available.

9Physical and chemical properties

Physical State

Liquid

Appearance

Clear, colourless to faintly yellow aqueous solution

Properties

Odor: Odourless to faint aromatic odour (benzyl alcohol)
Ph: Approximately 4.5–7.0 (bacteriostatic water, USP) unless adjusted
Melting: About 0 °C (aqueous solution)
Boiling: About 100 °C (aqueous solution)
Flash: Not flammable; aqueous solution (benzyl alcohol flash point 93–101 °C, present at 0.9%)
Vapour: As water (about 2.3 kPa at 20 °C)
Density: About 1.00–1.02 g/mL at 20 °C
Solubility: Aqueous solution; miscible with water
Logp: No data available
Decomp: Not applicable (aqueous solution); dissolved peptide degrades on heating

10Stability and reactivity

Stability And Reactivity

Reactivity: No dangerous reactions known; no decomposition if used according to specifications (Cayman)
Incompatible: No further relevant information available (Cayman); generic: strong oxidizing agents, strong acids/bases
Decomposition: No dangerous decomposition products known (Cayman); combustion yields carbon oxides, nitrogen oxides, sulfur oxides
Conditions To Avoid: No further relevant information available; store -20 °C desiccated and dark (lyophilized); reconstituted drug product must be used immediately per label

Conditions To Avoid

No data available.

Incompatible Materials

No data available.

11Toxicological information

Toxicological Information: Acute toxicity, oral
No data available

Acute toxicity, dermal
No data available

Acute toxicity, inhalation
No data available

Skin corrosion/irritation
No irritant effect (Cayman)

Serious eye damage/irritation
No irritating effect (Cayman)

Respiratory or skin sensitisation
No sensitizing effects known (Cayman). Clinical: hypersensitivity reactions and injection-site reactions reported with Egrifta

Germ cell mutagenicity
No data available

Carcinogenicity
Not listed by IARC, NTP or OSHA (Cayman)

Reproductive toxicity
No data available in SDS. Egrifta prescribing information: contraindicated in pregnancy (formerly Pregnancy Category X) and developmental toxicity was observed in animal studies - reproductive-toxicity concern for a GHRH-analogue hormone (see notes)

STOT, single exposure
No data available

STOT, repeated exposure
No data available

Aspiration hazard
No data available
Routes Of Exposure: Accidental needle-stick injection; skin and eye contact from splashes; ingestion is unlikely.
Symptoms: No specific symptoms are known. Pharmacologically active material: systemic effects consistent with its mechanism of action are possible after accidental injection, ingestion or absorption.

12Ecological information

Ecological Information: Cayman: Water hazard class 1 (self-assessment), slightly hazardous for water; no aquatic toxicity, persistence or bioaccumulation data.

13Disposal considerations

Disposal Guidance: No data available.

14Transport information

Transport Classification

Note: Not regulated as a dangerous good for transport by road (DOT 49 CFR), air (IATA/ICAO) or sea (IMDG). Not a marine pollutant. Ship refrigerated or frozen as required by Section 7; the coolant (dry ice, UN 1845) is regulated when used.

15Regulatory information

Regulatory Information

Tsca: Substance is not listed (Cayman)
Carcinogen Listings: Not listed by IARC, NTP, OSHA or EPA
Dea: Not a controlled substance
Other: FDA-approved prescription drug (Egrifta / Egrifta SV / Egrifta WR, Theratechnologies). WADA remark: tesamorelin is explicitly named on the WADA Prohibited List (S2 Peptide hormones, growth factors - GHRH and its analogues).

Carcinogen Listings

No data available.

16Other information

Revision: October 3, 2026
Sources Consulted: Cayman Chemical

Cayman Chemical product page

Sigma-Aldrich

Sigma-Aldrich / Supelco

MilliporeSigma

Sigma-Aldrich BVBA

Aldrich

American Regent - Sterile Water for Injection, USP

Hospira/Pfizer - Bacteriostatic Water for Injection
Confidence: medium
Additional Information: GHRH analogue. WADA Prohibited List class S2.

Back to SDS list